EARLY-STAGE DRUGS IN CLINICAL DEVELOPMENT FOR ME, 2017
Clinical Trial Summary for Phase II Trial, RUBY
The acquisition was completed in March 2015 and created one of the world' s TOP ## PHARMACEUTICAL COMPANIES BASED AROUND A NEW " GROWTH PHARMA" BUSINESS MODEL (ALLERGAN, PRESS RELEASE, MARCH ##, 2015).
OTHER DRUGS IN PHASE II OF CLINICAL DEVELOPMENT FOR HIV, 2016
VIIV'S DOLUTEGRAVIR/LAMIVUDINE - PHASE III CLINICAL TRIALS
THE SAFETY AND EFFICACY OF THE NOVEL PI-BASED COMBINATION IS CURRENTLY BEING EVALUATED IN TWO PHASE III CLINICAL TRIALS IN TREATMENT-NAÏVE AND TREATMENT-EXPERIENCED HIV-##-INFECTED ADULTS (JANSSEN PHARMACEUTICALS, NCT##; JANSSEN PHARMACEUTICALS, NCT##).
The agreement allows TT-## to be co-marketed by Teijin Pharma Limited, the core company of the Teijin Group' s medical and pharmaceutical business, and Taisho Toyama Pharmaceutical Co., Ltd. of the Taisho Pharmaceutical Group.